A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia
Latest Information Update: 13 Oct 2024
Price :
$35 *
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 02 Aug 2022 Status changed from active, no longer recruiting to completed, according to an Esperion Therapeutics media release.
- 03 Mar 2022 Planned End Date changed from 1 Apr 2022 to 1 May 2022.
- 03 Mar 2022 Status changed from recruiting to active, no longer recruiting.